Spine Wave, a Shelton, Conn.-based spine device company, has initiated a clinical study in Europe to gather data on the second generation of its NuCore Injectable Nucleus Device for the percutaneous treatment of degenerative disc disease, according to a Spine Wave news release.
The NuCore material is made from a synthetic polymer designed to mimic the properties of a natural nucleus. The new version of the device includes a transient radiopacifier for the intraoperative visualization of the material using fluoroscopy during the percutaneous injection.
The new study will be added to existing data from 68 patients with a two-year follow up.
Related Articles on Spine Devices:
Neuralstem Receives Approval for Cervical Spine Neural Stem Cell Injections to Treat ALS
Synthes Quarterly Revenues Break $1B for the First Time, Thanks to International Markets
K2M Hires 3 New International Team Leaders
The new study will be added to existing data from 68 patients with a two-year follow up.
Related Articles on Spine Devices:
Neuralstem Receives Approval for Cervical Spine Neural Stem Cell Injections to Treat ALS
Synthes Quarterly Revenues Break $1B for the First Time, Thanks to International Markets
K2M Hires 3 New International Team Leaders